BioScrip Appoints Richard Denness as Chief Commercial Officer

DENVER, July 10, 2018 (GLOBE NEWSWIRE) — BioScrip, Inc. (NASDAQ:BIOS) (“BioScrip” or the “Company”), the largest independent national provider of infusion and home care management solutions, today announced the appointment of Richard Denness as Senior Vice President, Chief Commercial Officer of the Company, effective July 9, 2018.

Mr. Denness brings 29 years of healthcare experience to BioScrip, including two decades in executive leadership roles.  Key positions held by Mr. Denness include General Manager, Australia/New Zealand at Schering-Plough, President at IVAX Laboratories (now Teva Respiratory), Vice President and General Manager, Neurology at UCB, CEO of Vycor Medical, and Managing Director at Proudfoot Consulting.  Most recently, he held the position of Managing Director and Global Healthcare Lead at North Highland Consulting.  His vast experience in leading teams to achieve record results includes growing UCB’s epilepsy franchise nearly five-fold, into a global market leader, while establishing the biopharmaceutical company’s first blockbuster medication exceeding $1 billion in annual revenue.  Mr. Denness possesses highly-relevant commercial experience in sales, marketing, and managed care, complemented by a deep strategic background.

“On behalf of our Board of Directors and management team, I am thrilled to welcome Rich to BioScrip,” said Daniel E. Greenleaf, President and Chief Executive Officer. “He brings us extensive healthcare experience, is results driven, and has a proven track record of driving profitable growth and achieving targeted metrics, while providing visionary and collaborative leadership, throughout his career.  Rich’s appointment rounds out our best-in-class senior management team, positioning us well to capture the enormous potential of BioScrip and the home infusion marketplace.”

Mr. Denness commented, “I am very excited to join BioScrip at this pivotal time in its transformation and look forward to working closely with senior leadership to drive profitable growth and value-creation for all stakeholders.  BioScrip’s independent national platform and dedicated workforce, which is singularly focused on providing the highest standard of care to infusion therapy patients in the home setting, underpin my confidence in the Company’s future.”  

About BioScrip, Inc.

BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,200 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Investor Contacts:

Stephen Deitsch
Chief Financial Officer & Treasurer 
T:  (720) 697-5200
stephen.deitsch@bioscrip.com

Kalle Ahl, CFA
The Equity Group
T:  (212) 836-9614
kahl@equityny.com  

Primary Logo

Leave a Comment